FINACCESS - Finnish National Study for Early Access to Cancer Therapies

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524769-26-00

Enrollment

1500

Registered

2026-05-08

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

To evaluate the anti-tumor activity and toxicity of anti-cancer drugs that are approved or under review for approval by EMA, FDA or PMDA, or for which otherwise sufficient safety data has been established, and are used for the treatment of patients with cancer.

Detailed description

To perform optional biomarker analyses including (but not limited to) next generation sequencing on fixed and fresh tumor samples or liquid biopsies, To define possible pathway activations and resistance mechanism facilitating progression to given therapies

Interventions

DRUGBI 1810631

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To evaluate the anti-tumor activity and toxicity of anti-cancer drugs that are approved or under review for approval by EMA, FDA or PMDA, or for which otherwise sufficient safety data has been established, and are used for the treatment of patients with cancer.	—

Secondary

Measure	Time frame
To perform optional biomarker analyses including (but not limited to) next generation sequencing on fixed and fresh tumor samples or liquid biopsies, To define possible pathway activations and resistance mechanism facilitating progression to given therapies	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 12, 2026